VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

A2-CPA-CPB(-CTE)-recombinant L. tarentolae L. infantum SMT Protein Vaccine Leishmania infantum HSP70 II mutant vaccine pcDNA3-LiP0 VVr expressing L. infantum P36/LACK
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004628
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector: (Saljoughian et al., 2013)
  • Preparation: Recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinases (CPA and CPB without its unusual C-terminal extension (CPB(-CTE))) as a tri-fusion gene (Saljoughian et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004066
  • Type: Subunit vaccine
  • Status: Research
  • SMT gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: MPL vaccine adjuvant
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0003006
  • Type: Live, attenuated vaccine
  • Status: Research
  • HSP70 II gene engineering:
    • Type: Gene mutation
    • Detailed Gene Information: Click Here.
  • Preparation: The HSP70-II null mutant (∆hsp70-II::NEO/∆hsp70-II::HYG) is a cloned line that was generated by targeted deletion of both HSP70-II alleles in the L. infantum strain MCAN/ES/96/BCN150 [32]. L. major promastigote (strain MHOM/IL/80/Friedlin; clon V1) were also used in this study. Promastigotes of both species were grown in RPMI 1640 culture medium supplemented with 10% heatinactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (Carrion et al., 2011).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Product Name: DNA Vaccine encoding LIPO-A Protein of L. infantum
  • Vaccine Ontology ID: VO_0004197
  • Type: DNA vaccine
  • Status: Research
  • Antigen: LiP0
  • LIPO-A gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: Eukaryotic expression plasmid pcDNA3 (Invitrogen, San Diego, Calif.) (Iborra et al., 2003)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004198
  • Type: Recombinant vector vaccine
  • Status: Research
  • Antigen: L. infantum p36/LACK protein
  • P36/LACK gene engineering:
    • Type: Recombinant vector construction
    • Description: The gene encoding L. infantum p36/LACK protein was expressed by recombinant vaccinia virus, and co-expressed murine IL-12 (Gonzalo et al., 2001).
    • Detailed Gene Information: Click Here.
  • Adjuvant: IL-12 vacince adjuvant
  • Vector: Recombinant vaccinia virus (VVr) derived from the wild-type Western Reserve strain (WR) (Gonzalo et al., 2001).
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Vaccination Protocol: Group 1 (DNA cSLN/Live) immunized with pcDNA-A2-CPA-CPB-CTE-cSLN (50 µg of pcDNA-A2-CPA-CPB-CTE formulated by cSLN nanoparticles as a chemical delivery as previously described [59] as a prime and with 2×107 recombinant L. tarentolae A2-CPA-CPB-CTE as a boost; group 2 (L. tarentolae Live A2-CPA-CPB-CTE/L. tarentolae Live A2-CPA-CPB-CTE) vaccinated with 2×107 recombinant L. tarentolae-A2-CPA-CPB-CTE as prime and boost; group 3 (PBS as a control); group 4 [(empty vector pcDNA-cSLN (prime)/Live L. tarentolae wild type (boost) as a control)]; and group 5 (L. tarentolae Live/L. tarentolae Live) vaccinated with 2×107 L. tarentolae wild type as prime and boost and used as a control. All groups were immunized via footpad (Saljoughian et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Three weeks after the last immunization, all animals were challenged with 107 stationary phase L. infantum promastigotes by lateral tail vein (Saljoughian et al., 2013).
  • Efficacy: Our results showed that immunization with both prime-boost A2-CPA-CPB(-CTE)-recombinant L. tarentolae protects BALB/c mice against L. infantum challenge (Saljoughian et al., 2013).

Mouse Response

  • Host Strain: C57BL/6
  • Vaccination Protocol: Mice were immunized with 10 μg of rSMT plus 20 μg of MPL®-SE in a volume of 0.1 ml. Another group of mice was administrated with 10 μg of rSMT alone. Control groups received either saline or MPL®-SE alone. The mice were immunized subcutaneously three times at three weeks intervals in the right hind footpad and at the base of the tail (Goto et al., 2007).
  • Challenge Protocol: Mice were challenged with L. infantum three weeks after the last immunization. 5 × 106 L. infantum promastigotes were suspended in Hank's balanced salt solution and injected i.v. into the tail vein of the mouse (Goto et al., 2007).
  • Efficacy: Significant reduction of parasites was seen in mice immunized with rSMT plus MPL®-SE compared with those in saline or adjuvant alone groups. The immunized mice showed 43-fold and 55-fold reduction in the number of parasites in spleens, 111-fold and 117-fold reduction in livers compared with saline and adjuvant alone groups, respectively (Goto et al., 2007).

Mouse Response

  • Host Strain: BALB/c mouse
  • Persistence: L. infantum parasites lacking the HSP70-II gene have a virulence greatly reduced (Carrion et al., 2011).
  • Efficacy: Inoculation of ∆HSP70-II parasites protects BALB/c mice against L. major challenge (Carrion et al., 2011).
  • Host Ighv1-9 response
    • Description: The IgG2a titers were high for all groups with differing inoculation routes, suggesting that infection with ΔHSP70-II parasites, independent of the inoculation route, leads to a predominant production of anti-Leishmania antibodies of the IgG2a isotope. Antibody titers were determined by ELISA before and 4 weeks after inoculation and showed an increase between the two samples. IgG2a titers were significantly higher than IgG1 titers (Carrion et al., 2011).
    • Detailed Gene Information: Click Here.

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: In DNA immunization experiments, mice were inoculated twice intramuscularly (i.m.) in both quadriceps with 100 μg of DNA (50 μg per leg) of either pcDNA3-LiP0 or pcDNA3 (controls) in a total volume of 100 μl of PBS. When “prime-boost” immunization was carried out, two inoculations of DNA and two inoculations of recombinant protein were administered. In all groups, the mice were inoculated at 2-week intervals (Iborra et al., 2003).
  • Challenge Protocol: Two weeks after the final inoculation, immunized mice were challenged with 5 × 104 stationary-phase promastigotes of L. major that were suspended in 50 μl of PBS and injected into the left hind footpad (Iborra et al., 2003).
  • Efficacy: Three weeks after challenge, the parasite burden was found to be significantly lower in mice vaccinated with pcDNA3-LiP0 than in controls. Mice vaccinated with LiP0-DNA had a 99.1% reduction in the parasite burden 3 weeks after infection compared with mice vaccinated with control DNA (Iborra et al., 2003).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were primed with VVr (5 × 107 PFU/mouse) by the intraperitoneal (i.p.) route. Two weeks later (14 days p.i.), animals were boosted with VVr or recombinant p36 antigen (Gonzalo et al., 2001).
  • Challenge Protocol: 35 days p.i., mice were challenged in the right hind foot with 105 of L. major stationary-phase promastigote culture (Gonzalo et al., 2001).
  • Efficacy: BALB/c mice immunized with a DNA vector expressing p36/LACK of Leishmania infantum followed by a booster with VVp36/LACK induced significant protection against Leishmania major infection (Gonzalo et al., 2001).
References References References References References
Saljoughian et al., 2013: Saljoughian N, Taheri T, Zahedifard F, Taslimi Y, Doustdari F, Bolhassani A, Doroud D, Azizi H, Heidari K, Vasei M, Namvar Asl N, Papadopoulou B, Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS neglected tropical diseases. 2013; 7(4); e2174. [PubMed: 23638195].
Goto et al., 2007: Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine. 2007; 25(42); 7450-7458. [PubMed: 17804125].
Carrion et al., 2011: Carrion J, Folgueira C, Soto M, Fresno M, Requena JM. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasites & vectors. 2011; 4(1); 150. [PubMed: 21794145].
Iborra et al., 2003: Iborra S, Soto M, Carrión J, Nieto A, Fernández E, Alonso C, Requena JM. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infection and immunity. 2003; 71(11); 6562-6572. [PubMed: 14573678].
Gonzalo et al., 2001: Gonzalo RM, Rodríguez JR, Rodríguez D, González-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes and infection / Institut Pasteur. 2001; 3(9); 701-711. [PubMed: 11489418].